NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

http://www.wikidata.org/entity/Q33710760

about

Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells Natural Killer Cells for Therapy of Leukemia Recent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescents Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy Cellular immunotherapy as a beacon of hope for hematological malignancies T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect Natural killer cell biology: an update and future directions How I treat pediatric acute myeloid leukemia Killer immunoglobulin-like receptors and tumor immunity Childhood acute myeloid leukaemia Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects.Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice Targeted immunotherapy for acute myeloid leukemia Novel therapeutic options in Acute Myeloid Leukemia Genetic barriers in transplantation medicine Monitoring of the Immune Dysfunction in Cancer Patients "Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy The new deal: a potential role for secreted vesicles in innate immunity and tumor progression Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy Improving natural killer cell cancer immunotherapy Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process Chemical metabolic inhibitors for the treatment of blood-borne cancers Cytotoxicity of activated natural killer cells against pediatric solid tumors.Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation.Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report Allogeneic natural killer cells for refractory lymphoma IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.

P2860

Q21245481-60756F11-AF87-4CB0-A303-63373D5DB573 Q26745906-0D860FD8-40AD-4158-A9D4-F0989B661F94 Q26750995-00E14BA9-8DF3-4C83-A661-2048265F565A Q26770391-53B86B2B-9CFF-406A-9AE0-C40CBBD15E29 Q26773135-CF2F7154-30A4-4FE8-8D0E-199ED0C2CFD0 Q26774678-FBE1B273-3857-454F-AB4E-A61B97DF6331 Q26777209-86BB783B-6D0A-47E5-A42D-6939B13F1E7D Q26784288-5FEAD584-E309-4AD1-81A9-DF64E68AD2AB Q26826830-41FBDD07-84C8-4AEB-905C-0CE39568D6F2 Q26830512-026A2315-1919-4D09-8B20-2C40ACE1BE4A Q26992280-9D461F23-894F-429B-9E31-00F653EC861B Q27005792-885EF3A9-34DC-4DBB-9785-2A2331A4D7D6 Q27005960-E66A847B-8153-4AE4-99CC-3C93EE88AB5D Q27301956-A6007033-3C42-426B-8D82-E6F13FE764D8 Q27309991-0795FA71-0443-4074-96D8-BB39FCB3A96A Q27318729-0158DF0D-1D77-40C7-9B74-264A592442F1 Q27687636-AD236FF1-52CA-4232-8AD7-31E55F92DF37 Q28069889-30F61080-BD52-474C-A7CA-7C190A86682A Q28069956-DBEE7F8C-C6FF-4878-ADDF-F591747784B2 Q28072712-5E3D1FAF-0718-423E-8180-869ED36081FC Q28081338-017D68E0-DE66-4FDF-94C8-52E1B31160BD Q28084891-091CF643-F343-46E6-8AF1-3B9664172C84 Q28085397-8CF1BB64-4B7D-4DE1-996A-8CCD5C6B927D Q28087719-08401ABF-DBEB-4425-AB52-DC42D7D5CAF1 Q28266580-890FF63A-E0CA-4EA9-853D-858B1D1173DF Q28743568-5005A8CB-F68F-4991-8734-55A2E62D5FC1 Q28822335-03F889E7-D614-4E09-8377-9F73D4DC19C4 Q30503995-E0A4619A-2214-48B8-BF80-897CAFFB4BD1 Q31118586-2ABFC613-CD27-47DC-B2CA-A4FEAE69BFF2 Q33600093-91E6A809-BCCA-4D76-ADEB-E3B16CCFA8D3 Q33703046-5050E97F-EDE2-42FF-954E-8D31FE25E60E Q33748308-632D31FA-20AA-46B7-B581-A7D65079E2F8 Q33850138-417E94FF-7B25-417D-BE19-41DD08EF0C7A Q34077847-FD527785-B3C4-4BB2-A294-8482081BA707 Q34084756-10D81252-93EB-42EE-AFF3-201411BF7B7B Q34132358-57671728-16CD-49B0-9551-BA6CE8F851A8 Q34166288-E5E6CB48-B8AD-4FD7-BFD0-F063DDB78CB9 Q34180695-89EF12FB-FE4C-4FA5-A283-81A176DF66B9 Q34307792-ADEE65FA-00CD-433A-98B1-4AFE54527B72 Q34344617-CEF25FF1-EB27-4F37-8C0D-83D724B4CC15

P2860

NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

http://www.wikidata.org/entity/Q33710760

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

NKAML: a pilot study to determ ...... ldhood acute myeloid leukemia.

@ast

NKAML: a pilot study to determ ...... ldhood acute myeloid leukemia.

@en

type

label

NKAML: a pilot study to determ ...... ldhood acute myeloid leukemia.

@ast

NKAML: a pilot study to determ ...... ldhood acute myeloid leukemia.

@en

prefLabel

NKAML: a pilot study to determ ...... ldhood acute myeloid leukemia.

@ast

NKAML: a pilot study to determ ...... ldhood acute myeloid leukemia.

@en

P1433

Q33710760-BA83E166-4CA9-481F-9321-A31789D458C3

P1476

Q33710760-800BCE73-C0B4-4075-8F18-F8313CDED27B

P2093

Q33710760-0FB425CB-09B0-4532-8EB5-30E5A1382D6E

Q33710760-6251BEBB-1F69-4AEA-8611-6CF5BA6DA575

Q33710760-A1CF2A2C-16CB-437C-A7F7-FBB55BB32D2E

Q33710760-A62625D6-2D1B-4338-91E3-1C68860263F2

Q33710760-BF434EC2-AC33-4667-A75B-F8FD3E9031E5

Q33710760-F1EE616F-0AA2-4937-BE20-34C759FE3412

P2860

Q33710760-07BC1C78-29C8-4D79-BBD7-FA7CAF160D0A

Q33710760-0824B638-DDFD-4B75-8372-E16E61E08FC8

Q33710760-0F064BF4-006C-4A7C-99BB-701A6CCECB9A

Q33710760-23080D24-0472-43B8-9944-C589B5AEA02D

Q33710760-250D0965-DEBA-4675-9212-B46D204BCD6C

Q33710760-2AFDCF00-3C6B-4011-AEFD-6E71063D9795

Q33710760-2B1D9B61-0616-4734-86F9-66A5A624C728

Q33710760-35E1F497-FBAB-45C1-A2DB-2441BD6CA653

Q33710760-385A7A18-60FE-4648-A6A0-1CDEE639AF10

Q33710760-3E713F67-4A6B-4E39-B817-15C92B5E5682

P304

Q33710760-1D112B1C-C345-4607-87CE-084578BB5359

P31

Q33710760-38C277F1-4EAB-4176-8C2E-0EBF3DFEBD68

P356

Q33710760-57D80C1F-16E5-4CA2-B6E0-32C7A239BCA2

P407

Q33710760-F0A9EFD7-9139-4322-ABD7-478509C93CF1

P433

Q33710760-E1068834-96B9-4758-BBFE-753DB4664892

P478

Q33710760-35FFFA09-B39A-44DB-8DBF-8935041D7C1E

P50

Q33710760-2AACD040-ADB4-4E34-A035-E56F2B95FF87

Q33710760-81C38F31-8BB3-4A20-8B47-112AA50C89C6

P577

Q33710760-78815515-3A22-4C6C-8BFC-56AB47766325

P698

Q33710760-0F76366E-6BB7-4363-87DD-816CA4DEB1C7

P921

Q33710760-CC82BF1F-B85F-4B87-ACD3-29BA44901005

P932

Q33710760-FBD711CD-2110-4284-911A-30AE88DFC64F

P356

JCO.2009.24.4590

P1433

Journal of Clinical Oncology

P1476

NKAML: a pilot study to determ ...... ldhood acute myeloid leukemia.

@en

P2093

Barbara Rooney

http://www.w3.org/2001/XMLSchema#string

Hiroto Inaba

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Rubnitz

http://www.w3.org/2001/XMLSchema#string

Raul C Ribeiro

http://www.w3.org/2001/XMLSchema#string

Stanley Pounds

http://www.w3.org/2001/XMLSchema#string

Wing Leung

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.

Hematopoietic stem-cell transplantation.

Human natural killer cells.

Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method.

Determinants of antileukemia effects of allogeneic NK cells.

P304

955-959

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.24.4590

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20085940

http://www.w3.org/2001/XMLSchema#string

P921

P932

2834435

http://www.w3.org/2001/XMLSchema#string